Curis (NASDAQ:CRIS – Get Free Report) is projected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Curis to post earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Stock Performance
Shares of NASDAQ:CRIS opened at $3.09 on Friday. Curis has a fifty-two week low of $2.86 and a fifty-two week high of $17.49. The firm has a fifty day moving average price of $3.32 and a 200 day moving average price of $4.31. The firm has a market cap of $26.18 million, a price-to-earnings ratio of -0.40 and a beta of 3.41.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Curis in a research note on Tuesday, December 10th.
About Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
See Also
- Five stocks we like better than Curis
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- The How and Why of Investing in Gold Stocks
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
